Cargando…

CD44 Contributes to the Regulation of MDR1 Protein and Doxorubicin Chemoresistance in Osteosarcoma

Osteosarcoma is the most common type of pediatric bone tumor. Despite great advances in chemotherapy during the past decades, the survival rates of osteosarcoma patients remain unsatisfactory. Drug resistance is one of the main reasons, leading to treatment failure and poor prognosis. Previous repor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gerardo-Ramírez, Monserrat, Keggenhoff, Friederike L., Giam, Vanessa, Becker, Diana, Groth, Marco, Hartmann, Nils, Straub, Beate K., Morrison, Helen, Galle, Peter R., Marquardt, Jens U., Herrlich, Peter, Hartmann, Monika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9368984/ https://www.ncbi.nlm.nih.gov/pubmed/35955749 http://dx.doi.org/10.3390/ijms23158616

Ejemplares similares

Deletion of Cd44 Inhibits Metastasis Formation of Liver Cancer in Nf2-Mutant Mice
por: Gerardo-Ramírez, Monserrat, et al.
Publicado: (2023)

DHFR and MDR1 upregulation is associated with chemoresistance in osteosarcoma stem-like cells
por: Lee, Yu-Hsien, et al.
Publicado: (2017)

Pleiotrophin promotes chemoresistance to doxorubicin in osteosarcoma by upregulating P-glycoprotein
por: Wu, Dapeng, et al.
Publicado: (2017)

CD44 drives aggressiveness and chemoresistance of a metastatic human osteosarcoma xenograft model
por: Mayr, Lisa, et al.
Publicado: (2017)

Enrichment of CD44 in Exosomes From Breast Cancer Cells Treated With Doxorubicin Promotes Chemoresistance
por: Wang, Xiaohong, et al.
Publicado: (2020)

Luteolin attenuates the chemoresistance of osteosarcoma through inhibiting the PTN/β-catenin/MDR1 signaling axis by upregulating miR-384
por: Qin, Tao, et al.
Publicado: (2022)

Growth factor and co-receptor release by structural regulation of substrate metalloprotease accessibility
por: Parra, Liseth M., et al.
Publicado: (2016)

Ecdysteroids Sensitize MDR and Non-MDR Cancer Cell Lines to Doxorubicin, Paclitaxel, and Vincristine but Tend to Protect Them from Cisplatin
por: Martins, Ana, et al.
Publicado: (2015)

Molecular mechanisms of chemoresistance in osteosarcoma (Review)
por: HE, HONGTAO, et al.
Publicado: (2014)

Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925
por: Yang, X, et al.
Publicado: (2014)

Targeting the CtBP1-FOXM1 transcriptional complex with small molecules to overcome MDR1-mediated chemoresistance in osteosarcoma cancer stem cells
por: Chen, Xun, et al.
Publicado: (2021)

LncRNA H19 is a major mediator of doxorubicin chemoresistance in breast cancer cells through a cullin4A-MDR1 pathway
por: Zhu, Qiong-Ni, et al.
Publicado: (2017)

miR‐495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression
por: Zou, Zhenyou, et al.
Publicado: (2017)

Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality
por: Yu, Lei, et al.
Publicado: (2022)

Chemotherapy induces feedback up-regulation of CD44v6 in colorectal cancer initiating cells through β-catenin/MDR1 signaling to sustain chemoresistance
por: Ghatak, Shibnath, et al.
Publicado: (2022)

Albumin nanoformulations as an innovative solution to overcome doxorubicin chemoresistance
por: Bessone, Federica, et al.
Publicado: (2021)

A lysosome-targeted dextran-doxorubicin nanodrug overcomes doxorubicin-induced chemoresistance of myeloid leukemia
por: Zeng, Yunxin, et al.
Publicado: (2021)

Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance
por: Wang, Dong-Yu, et al.
Publicado: (2016)

TGM2 knockdown reverses cisplatin chemoresistance in osteosarcoma
por: Li, Cuiyun, et al.
Publicado: (2018)

Association between MDR1 polymorphisms and XELIRI and XELOX chemoresistance in Saudi patients with colorectal cancer
por: Al-Ghafari, Ayat B., et al.
Publicado: (2020)

Hedgehog−Gli2 Signaling Promotes Chemoresistance in Ovarian Cancer Cells by Regulating MDR1
por: Wang, Qian, et al.
Publicado: (2022)

Gamma secretase dependent release of the CD44 cytoplasmic tail upregulates IFI16 in cd44(-/-) tumor cells, MEFs and macrophages
por: Schultz, Kristin, et al.
Publicado: (2018)

MDR1 Inhibition Reverses Doxorubicin-Resistance in Six Doxorubicin-Resistant Canine Prostate and Bladder Cancer Cell Lines
por: Packeiser, Eva-Maria, et al.
Publicado: (2023)

Acquired Resistance to Antiangiogenic Therapies in Hepatocellular Carcinoma Is Mediated by Yes‐Associated Protein 1 Activation and Transient Expansion of Stem‐Like Cancer Cells
por: Castven, Darko, et al.
Publicado: (2021)

Combining GRP78 suppression and MK2206-induced Akt inhibition decreases doxorubicin-induced P-glycoprotein expression and mitigates chemoresistance in human osteosarcoma
por: Xia, Yuan-Zheng, et al.
Publicado: (2016)

Doxorubicin-induced novel circRNA_0004674 facilitates osteosarcoma progression and chemoresistance by upregulating MCL1 through miR-142-5p
por: Ma, Xiao-Long, et al.
Publicado: (2021)

Association of Loss of Heterozygosity at the p53 Locus with Chemoresistance in Osteosarcomas
por: Goto, Akiteru, et al.
Publicado: (1998)

Can Denosumab be used in combination with Doxorubicin in Osteosarcoma?
por: Punzo, Francesca, et al.
Publicado: (2020)

Exosomal miR-331-3p derived from chemoresistant osteosarcoma cells induces chemoresistance through autophagy
por: Meng, Chenyang, et al.
Publicado: (2023)

GFRA1: A Novel Molecular Target for the Prevention of Osteosarcoma Chemoresistance
por: Kim, Mihwa, et al.
Publicado: (2018)

Leptin acts on mesenchymal stem cells to promote chemoresistance in osteosarcoma cells
por: Feng, Helin, et al.
Publicado: (2020)

Phenotypic Basis for Matrix Stiffness-Dependent Chemoresistance of Breast Cancer Cells to Doxorubicin
por: Joyce, M. Hunter, et al.
Publicado: (2018)

Light-Responsive Micelles Loaded With Doxorubicin for Osteosarcoma Suppression
por: Chen, Jiayi, et al.
Publicado: (2021)

Contribution of Mitochondrial Activity to Doxorubicin-Resistance in Osteosarcoma Cells
por: Giacomini, Isabella, et al.
Publicado: (2023)

Doxorubicin Dose Deintensification in Pediatric Osteosarcoma, Is Less Better?
por: Halalsheh, Hadeel, et al.
Publicado: (2023)

Salinomycin enhances doxorubicin-induced cytotoxicity in multidrug resistant MCF-7/MDR human breast cancer cells via decreased efflux of doxorubicin
por: KIM, KWANG-YOUN, et al.
Publicado: (2015)

Downregulation of CD44 reduces doxorubicin resistance of CD44(+)CD24(−) breast cancer cells
por: Van Phuc, Pham, et al.
Publicado: (2011)

LncRNA Sox2OT-V7 promotes doxorubicin-induced autophagy and chemoresistance in osteosarcoma via tumor-suppressive miR-142/miR-22
por: Zhu, Kewei, et al.
Publicado: (2020)

Silencing XIAP suppresses osteosarcoma cell growth, and enhances the sensitivity of osteosarcoma cells to doxorubicin and cisplatin
por: Qu, Yang, et al.
Publicado: (2022)

Microvascular invasion of hepatocellular carcinoma predicts microvascular invasion of its recurrence: potential implications for salvage liver transplantation?
por: Heinrich, Stefan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4ompo0gi79666ho7hvr9hj5hpq